The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
Abstract
The polycystic ovary syndrome (PCOS) is a complex clinical entity for the clinician, a scientific challenge for the investigator, and a frustrating personal and social experience for approximately 3.5–5.0 million women in the United States. It is classically defined by chronic anovulation and hyperandrogenism, but it has become apparent that insulin resistance plays a prominent role in the disorder. The discovery of the central role of insulin resistance in PCOS is important from several points of view, including the possibility that the traditional management of the disorder may have untoward long-term consequences. The aims of this report are to highlight why insulin resistance should be considered in the formulation of chronic treatment strategies of PCOS, to perhaps suggest a more judicious use of oral contraceptive pills (OCPs) in the chronic treatment of the disorder, and to issue a call for more rigorous and critical studies of the metabolic effects of both OCPs and insulin-sensitizing drugs in women with PCOS. For many decades OCPs have been standard therapy for women with PCOS not seeking pregnancy. There have been several advantages of treatment with OCPs, including foremost protection from the development of endometrial carcinoma, regularization of menses, and amelioration of hirsutism and acne. There is no disputing the importance of these benefits. However, what has been lacking is a critical examination of whether OCPs might also exert adverse metabolic effects with long-term consequences, especially in a group of women with known insulin resistance and predisposition to type 2 diabetes and cardiovascular disease. Numerous studies have documented that both lean and obese women with PCOS are insulin resistant (1–4). The lean woman with PCOS seems to have a form of insulin resistance that is intrinsic (and perhaps unique) to the syndrome and poorly understood (5–7). The obese woman with PCOS possesses not only the form of insulin resistance intrinsic to the syndrome, but also has an added burden of insulin resistance that is related to excess adiposity (8). Insulin resistance is associated with an increased risk for several disorders, including type 2 diabetes, hypertension, dyslipidemia (low high-density lipoprotein cholesterol and high triglycerides), elevated plasminogen activator inhibitor type 1 (PAI-1), elevated endothelin-1, endothelial dysfunction, and heart disease. This clustering of abnormalities with insulin resistance has been termed Syndrome X, the insulin resistance syndrome, or the dysmetabolic syndrome (9, 10). The adverse potential of the dysmetabolic syndrome has recently been highlighted by the National Cholesterol Education Projects Adult Treatment Panel III guidelines, which recognize Syndrome X as a major cardiac risk factor (11), and by assignment of an ICD-9 code (277.7) for the disorder. PCOS may rightly be considered a component of the dysmetabolic syndrome in women. Evidence that PCOS is associated with a high risk for the development of type 2 diabetes and heart disease is mounting, and optimal chronic therapy for the disorder should address these long-term general health issues. Regarding diabetes risk, prospective clinical trials have demonstrated a 31–35% prevalence of impaired glucose tolerance and 7.5–10.0% prevalence of type 2 diabetes mellitus in women with PCOS (12, 13). It has also been reported that the rate of conversion from impaired glucose tolerance to type 2 diabetes mellitus may be increased 5- to 10-fold in women with PCOS (12, 14). Oligomenorrhea is a highly predictive surrogate marker for PCOS. An analysis of 101,073 women in the Nurses’ Health Study II reported that over an 8-yr period the conversion rate to type 2 diabetes among oligomenorrheic women was approximately 2-fold greater than that for eumenorrheic women, regardless of whether the oligomenorrheic women were obese or lean, indicating that oligomenorrhea was an independent predictor of type 2 diabetes (15). Conversely, a retrospective study of an academic diabetes clinic in Virginia revealed that 27% of the premenopausal women with type 2 diabetes had PCOS (16), and transvaginal ultrasonography of premenopausal women in the diabetes clinic at Middlesex Hospital in England revealed an 82% prevalence of anatomically polycystic ovaries (17). Collectively, the above observations indicate that women with PCOS constitute one of the groups at highest risk for the development of diabetes. Although controversial, several lines of evidence also indicate increased cardiovascular risk in women with PCOS. PCOS is associated with increased prevalence of several cardiovascular risk factors, including hypertension (18–20) and dyslipidemia (21–24). In addition, women with PCOS display surrogate markers for early atherosclerosis, such as increased PAI-1 (25–27), endothelin-1 (28), and C-reactive protein (29) concentrations. Several (30–32), but not all (33), studies suggest that PCOS is associated with en
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Warram, J. H., Martin, B. C., Krolewski, A. S., Soeldner, J. S., & Kahn, C. R. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-909 · Cited by 1,038
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Low grade chronic inflammation in women with polycystic ovarian syndrome
Kelly, C. C. J., Lyall, H., Petrie, J. R., Gould, G. W., Connell, J. M. C., & Sattar, N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7580 · Cited by 640
Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
Legro, R. S., Kunselman, A. R., & Dunaif, A. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00948-2 · Cited by 622
Cited by
Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Self-citationPolycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Self-citation
Metadata
- Authors
- Diamanti-Kandarakis, E., Baillargeon, J.-P., Iuorno, M. J., Jakubowicz, D. J., & Nestler, J. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-05
- Volume
- 88
- Issue
- 5
- Pages
- 1927-1932
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1975142697
- Cited by
- 171
- References
- 19
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills. https://app.cochat.ai/papers/10.1210/jc.2002-021528
- The paper
- Diamanti-Kandarakis, E., Baillargeon, J.-P., Iuorno, M. J., Jakubowicz, D. J., & Nestler, J. E. (2003). A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-021528
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.